Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study
{{output}}
Background: No repigmentation treatments are approved for vitiligo affecting >10% body surface area (BSA). Objective: To assess efficacy and sa... ...
